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There has been enormous progress this past decade in the understanding of the biol-
ogy of dendritic cells (DCs) along with increasing attention for the development of novel
dendritic cell (DC)-based cancer therapies. However, the clinical impact of DC-based vac-
cines remains to be established. This limited success could be explained by suboptimal
conditions for generating potent immunostimulatory DCs as well as immune suppression
mediated by the tumor microenvironment (TME). Therefore, strategies that optimize the
potency of DC vaccines along with newly described therapies that target theTME in order
to overcome immune dysfunction may provide durable tumor-specific immunity. These
novel interventions hold the most promise for successful cancer immunotherapies.
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INTRODUCTION
Naturally occurring anti-tumor immune responses in cancer
patients and in murine tumor models are commonly impaired.
Tumor escape as a result of immuno-editing or through local
effects of the tumor microenvironment (TME) disables many
components of the immune response and ultimately limits the
success of immunotherapy. Suppression or modulation of tumor-
associated dendritic cell (DC) function by the TME is thought
to play a major role in impairing the development of potent
anti-tumor immune responses and promoting tumor progression.
This review provides an overview of the mechanisms by which
the tumor cells and tumor-associated cells co-opt many endoge-
nous host factors and physiological pathways in order to impair
immunogenic DC function. An updated overview of DC-based
tumor immunotherapies and strategies to target the TME in order
to overcome DC dysfunction and treat cancer patients will be
discussed. Understanding the underlying mechanisms involved in
the modulation of DC-based anti-tumor immunity by the TME
will provide opportunities for improving the efficacy of cancer
immune therapies.
DENDRITIC CELL BIOLOGY
The 2011 Nobel Prize in Medicine or Physiology was awarded
to Ralph Steinman for his discovery of dendritic cells (DCs) and
their role in adaptive immunity. DCs are the most potent profes-
sional antigen-presenting cells (APCs), able to activate adaptive
immunity through their capacity to sample the environment and
capture, process, and present antigens to T cells (1). Immature DCs
in peripheral tissues can capture antigens but due to absence of
co-stimulatory molecules, antigen presentation results in induc-
tion of tolerance through T-cell deletion, anergy and induc-
tion of regulatory, or suppressor T cells. Exposure to pathogens,
however, engages the process of maturation which guarantees a
well-controlled and targeted immune response.
While maturing, DCs lose their ability to capture antigen,
and acquire new features such as enhanced antigen processing
and presentation (through upregulation of surface MHC-II mol-
ecules); enhanced ability to migrate (through upregulation of the
chemokine receptor CCR7); and increased capacity to stimulate T
and B cells through cytokine secretion and co-stimulatory mole-
cules. DCs uptake antigens through different mechanisms (phago-
cytosis, macropinocytosis, and endocytosis) and process them into
peptides that are loaded on MHC molecules. The peptide/MHC
complexes are then presented to naïve T cells in the lymphoid
tissues. Binding of T cells to the MHC-antigen complex and co-
stimulatory molecules on DC surface (CD80, CD86, CD40) results
in the activation and subsequent differentiation of T cells into
effector cells endowed with unique functions and cytokine profiles,
capable of launching an antigen specific response. Extracellular
antigens (bacteria, parasites, toxins) are presented onto MHC-II
molecules and presented to CD4+ T cells whereas intracellular
antigens (viral proteins) are presented on MHC-I molecules to
CD8+ T cells. Importantly, DCs are the only APCs able to present
extracellular antigens onto MHC-I molecules to CD8+ T cells,
a process called cross-presentation that is crucial for anti-tumor
immunity, however, not all DC subsets may be capable of effi-
cient cross-presentation, and the degree to which they do may
be dependent upon the nature of the antigen and route of deliv-
ery. Myeloid DCs (mDCs, also know as classical or conventional
DCs) and plasmacytoid DCs (pDCs) are the two main subsets of
DCs. mDCs are key players in immune responses against path-
ogenic organisms and tumors. They differentiate from myeloid
progenitors, express CD11c and include the dermal DCs, Langer-
hans cells, interstitial DCs, and interdigitating DCs. mDCs are
found in peripheral tissues, lymphoid organs, and in the blood
and secrete large amounts of IL-12 upon activation. IL-12 medi-
ates enhancement of the cytotoxic activity of NK cells and CD8+
cytotoxic T lymphocytes, is involved in the differentiation of naive
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T cells into TH1 cells, and stimulates the production of interferon-
gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) by T
and NK cells cells. Blood mDCs includes BDCA1+ (CD1c+) and
BDCA3+ (CD141+) DCs. Recent studies have identified BDCA3+
(CD141+) DCs as the human counterpart of CD8α+ murine DCs
that share several phenotypic and functional properties such as
their expression of TLR3 and their ability to secrete IL-12 and
IFN-β. Although BDCA3+ DCs are widely thought to crosspre-
sent antigens more efficiently than other DC populations, new
findings show that DC populations may be comparably effective
at presenting exogenous antigens to CD8+ T cells as long as the
antigen is delivered to early endocytic compartments (2, 3).
Plasmacytoid DCs are the principal producers of type-I inter-
ferons (IFNs) in response to microbial and viral infection. They
express CD123, BDCA2, and BDCA4 and are primarily found in
blood and lymphoid organs such as the thymus, bone marrow,
spleen, tonsils, and lymph nodes under steady state conditions.
pDCs infiltrate various type of tumor but their role in anti-tumor
immune responses remains to be defined as some reports suggest
they can promote tumor growth (4).
Dendritic cell maturation involves the production of cytokines
that play a role in CD4+ T-cell polarization into TH1, TH2,
and TH17. Differentiation of TH1 cells, key players in immune
responses against intracellular pathogens, tumors, and viruses, is
driven by IL-12-mediated secretion. Development of TH2 cells,
involved in responses against parasites (but detrimental in the
setting of anti-tumor responses), is though to be induced by the
lack of IL-12 as well as by IL-4, thymic stromal lymphopoietin
(TSLP), and Matrix metalloproteinase 2 (MMP-2). TGF-β, IL-1β,
IL-6, and IL-23 have been implicated in TH17 polarization. DCs
can also induce naïve CD4+ T cells to differentiate into T follicular
helper cells whose function is to help B cells to differentiate into
antibody-secreting cells, as well as into regulatory T cells which
function is to suppress immune responses. DCs also play a role in
CD8+ T-cell differentiation into effector cytotoxic T lymphocytes.
In addition to their ability to mediate adaptive immunity, DCs acti-
vate innate immune responses, such as NK cells’ cytotoxicity and
cytokine production trough their secretion of IL-12, IL-18, and
type I-IFN. DCs also activate γδ T cells, another essential com-
ponent of the anti-tumor immune response. Finally, DCs are also
thought to play a role in the induction of effector memory T cells
(TEM) that differentiate into central memory T-cell (TCM), but
the mechanisms involved are still unclear. Altogether, these find-
ings make DCs the ideal candidate for cancer immunotherapy as
they activate overall immune responses.
Interestingly, it has been shown recently that in early stages
of tumor progression, DCs are immunocompetent and able to
induce the expansion of specific T-cell responses, whereas DCs
in advanced tumors become immunosuppressive (5). Under-
standing the underlying mechanisms involved in the modulation
of DC-based anti-tumor immunity by the TME will provide
opportunities for improving the efficacy of immune therapies.
TUMOR MICROENVIRONMENT: A HOT BED OF IMMUNO-SUPPRESSIVE
ACTIVITY
Despite the induction of tumor-specific T-cell responses in many
patients, DC vaccines have not translated into durable therapeutic
responses. Indeed, the TME employs several mechanisms that
inhibit DCs to induce efficient anti-tumor responses (Figure 1).
Immuno-suppressive molecules
Several tumor-derived factors such as IDO/TDO, CCL-2, VEGF,
TGF-β, M-CSF, GM-CSF, IL-6, and IL-10 have been reported
to negatively impact DC functions. TGF-β results in impair-
ment of DC function and accumulation/differentiation of Tregs,
myeloid-derived suppressor cells (MDSC), and detrimental M2
macrophages (6). IL-6 and M-CSF switch differentiation from
monocytes to macrophages rather than DCs (7). IL-10 is able
to convert immunostimulatory DCs into tolerogenic APCs and
induce anergic cytotoxic CD8+ T cells (8). We and others found
that inhibition of MAPK pathway in human BRAFV600E mutant
melanoma lines reduced production of immuno-suppressive
cytokines (IL-6, IL-10, VEGF) and restored IL-12 and TNF-α pro-
duction by DCs (9, 10). Stat3 is another signaling pathway that has
emerged as a critical regulator of immuno-suppressive cytokines.
An excellent review discusses various signaling pathways acti-
vated in cancers such as Stats, MAPK, and β-catenin (11). The
chemokine CCL2 recruits inflammatory monocytes which express
its receptor CCR2, as well as metastasis-associated macrophages,
therefore promoting malignancy (12). VEGF is involved in sev-
eral mechanisms of tumor pathophysiology such as inhibition
of DC differentiation (13). Several monoclonal antibodies have
been developed against VEGF or its receptor in order to prevent
angiogenesis and have shown clinical benefits in various cancers.
Activation of antigen-specific-Tregs for potent suppressor activity
has been shown to be achieved by pDCs and cDC through secretion
of the enzyme indoleamine 2,3-dioxygenase (IDO) (14, 15).
Regulatory T cells
CD4+ CD25+ Foxp3+ Tregs play a crucial role in maintaining
a suppressive environment and inhibiting anti-tumor responses.
Tregs express the inhibitory receptors CTLA-4, PD-1, and Tim-3
which contribute to their suppressive function through different
mechanisms (16). Some studies indicate that Tregs through CTLA-
4 can induce the down regulation of the co-stimulatory molecules
CD80 and CD86 on DCs (17). Moreover, Tregs compete for the
cytokine IL-2 with other immune cells through their expression
of its receptor CD25 with a 100-fold higher affinity (18). Similar
mechanisms might apply for other cytokines such as IL-7, IL-15,
and IL-12. Finally, Tregs can secrete two of the main immuno-
suppressive cytokines: IL-10 and TGF-β that blunt anti-tumor
effector cells such as CD4+, CD8+, and NK.
Immuno-suppressive myeloid cells
It is well established that subpopulations of myeloid cells are crit-
ical mediators of tumor initiation, angiogenesis and metastasis
and are able to inhibit anti-tumor immune responses through a
variety of mechanisms. MDSCs for instance play a crucial role
in immune evasion within tumors through several immuno-
suppressive mechanisms that blunt effector T-cell responses (19).
They suppress CD8+ T-cell anti-tumor immunity (20, 21) and
induce the differentiation of Tregs (22). Not only do they secrete
immuno-suppressive cytokines such as IL-10 but also express high
levels of NOS (nitric oxide synthase) involved in T-cell apopto-
sis (19, 23), and Arginase-1 which impair the local proliferative
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FIGURE 1 | Dysregulation of dendritic cell-mediated anti-tumor
immune responses by tumor microenvironment. Effector T cells can
recognize and kill tumor targets after activation by immunogenic dendritic
cells. However, a number of soluble mediators, including TGFβ, IL-10, and
alarmins, that are secreted by immuno-suppressive cells such as Treg
cells, MDSCs, and tumor cells can dysregulate dendritic cells function and
limit T-cell effector functions. (A) Exposure to pathogens induces the
maturation of immunogenic dendritic cells that secrete large amounts of
IL-12 upon activation. IL-12 mediates enhancement of the cytotoxic activity
of NK cells and CD8+ cytotoxic T lymphocytes, is involved in the
differentiation of naive T cells into TH1 cells, and stimulates the production
of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) from T
and NK cells cells. (B) In the tumor microenvironment, development of
detrimental/suboptimal TH2 cells is induced by alarmins such as TSLP, EDN,
and MMP-2 through mechanisms depending on inflammatory DCs.
(C) Immuno-suppressive cytokines such as IL-10 and TGF-β are responsible
for the induction of immature/tolerogenic/immuno-suppressive DCs able
to promote the accumulation of regulatory T cells. Tregs play a crucial role
in maintaining a suppressive environment and inhibiting anti-tumor
responses.
capacity of T cells (24). Macrophages have also been shown to
facilitate tumor growth. In the context of TME, macrophages
are skewed toward an M2-altered functional phenotype able to
produce lower levels of pro-inflammatory cytokines (IL-1β, TNF-
α, IL-12) and higher levels of immuno-suppressive cytokines
such as IL-10, TGF-β, and VEGF (25–27). Immunotherapeutic
approaches aimed at skewing detrimental M2 macrophages into
an immuno-competent M1 phenotype may promote effective
anti-tumor immunity.
Induction of TH2 cells through the expression of alarmins
Alarmins are naturally occurring endogenous mediators, rapidly
released in response to infection and/or tissue injury by several cell
types. These “danger signals” function to alert the host immune
system of cell and tissue trauma through activation and recruit-
ment of effector cells of innate and adaptive immunity (28). DCs
are able to sense alarmins present in the TME through surface and
intracellular receptors.
Matrix metalloproteinase 2 is expressed by cancer and/or stro-
mal cells and is associated with later tumor stages, increased
dissemination, and poorer prognosis/survival (29, 30). We have
shown that MMP-2 can directly modulate innate and adaptive
immune responses toward melanoma by not only being recog-
nized by specific CD4+ and CD8+ tumor-infiltrating T cells, but
also by modulating DC function to polarize TH2 responses. We
recently identified two pathways whereby MMP-2 functions as a
human endogenous “conditioner” that skews CD4+ T cells toward
a detrimental TH2 phenotype. MMP-2 degrades the type I IFN
receptor (IFNAR1), thereby preventing STAT1 phosphorylation
necessary for IL-12 production (31). Furthermore, we identified
that MMP-2 is a direct ligand for TLR2 on DCs, and found that
their interaction leads to OX40L up-regulation and TH2 skewing
(Godefroy et al., in revision).
Thymic Stromal Lymphopoietin has also been described to
modulate DC function and drive TH2 responses (32). TSLP pro-
duced by tumor cells has been shown to induce detrimental TH2
cells responsible for increasing tumor growth in breast cancer and
pancreatic cancer through the secretion of IL-13 and IL-4 (33, 34).
These findings support the idea that blocking antibodies for
MMP-2/TLR2 or TSLP/TSLPR interactions represent a promising
strategy for cancer therapy through their ability to polarize type-1
immune responses.
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Another alarmin, Eosinophil-derived neurotoxin (EDN) has
been shown to activate the TLR2–MyD88 signal pathway in DCs
and enhances TH2 immune responses (35).
Inhibition of antigen presentation by alteration of MHC molecules
and loss of tumor antigen expression
The TME alters the ability of DCs to effectively present antigen due
to a down regulation or loss of MHC molecules and genes associ-
ated with antigen presentation such as transporter associated with
antigen processing (TAP), low-molecular-weight protein (LMP),
and β2-microtubulin (36). Another mechanism of tumor escape
is the loss of tumor-associated antigens (TAA): the natural selec-
tion of tumor subclones poorly recognized by the immune system
which can thereby survive immune pressure (37).
Expression of inhibitory ligands
Immune checkpoints such as CTLA-4,PD-1,Tim-3,LAG3, ICOSL,
GITRl, and B7H3 are inhibitory receptors that regulate immune
responses to insure tolerance and prevent auto-immune diseases.
They will be discussed in section “Therapies Targeting TME.”
CD47, a ligand for SIRPα, is a “don’t eat me” signal for phagocytic
cells, whose function is to block phagocytosis. CD47 overexpres-
sion by human solid tumor cells represents another mechanism of
tumor escape by preventing tumor cells to be phagocytosed and
eliminated (38). Recent data has shown that its blockade by neu-
tralizing antibodies inhibits migration and metastasis in a variety
of tumor models.
Study of the TME is critical to better understand how tumors
harness surrounding cells to escape immunity and support their
growth. This combined with a better understanding of DC biology
should lead to the development of new strategies that effectively
restore DC activity and induce tumor detection and the generation
of potent anti-tumor responses.
DENDRITIC CELL-BASED TUMOR IMMUNOTHERAPIES
The immune system can eradicate tumors as shown by sponta-
neous regression of primary and metastatic melanoma (39) and
regression of tumors after adoptive transfer of T cells (40). The
potential for DCs to launch adaptive immunity makes them ideal
candidates for cancer immunotherapy (Figure 2). However this
approach alone does not overcome TME-induced DC dysregula-
tion. Therefore, targeting TME may improve the clinical benefit of
DC-based vaccines.
DC-BASED VACCINES
Ex vivo-generated DCs pulsed with antigens
The clinical impact of DC immunotherapy has been limited
despite the induction of tumor-specific T-cell responses in many
patients and occasional tumor regressions. At this point, the
first and only cell-based cancer vaccine approved by the FDA is
Provenge® from Dendreon. Provenge is an autologous antigen-
pulsed DC-based cancer vaccine for patients with metastatic
prostate cancer based on the results of a phase III randomized trial
that demonstrated a more than 4-month median improvement in
overall survival compared with a placebo vaccine. Overall, clinical
trials have demonstrated the feasibility and safety of DC vaccines
in phase I and II but have failed to demonstrate strong efficacy in
large phase III trials (41, 42).
Many reasons may explain this lack of success with DC vaccines.
There is currently no consensus on the optimal strategy to generate
FIGURE 2 | Anti-tumor immunotherapies. (A)There is currently no
consensus on the optimal strategy to generate DCs for
immunotherapeutic use regarding DC subsets, maturation stimuli, and
methods to load antigens. (B)Therapies aiming at reprograming the
immuno-suppressive TME are very promising, including blockade of
immune checkpoints as well as inhibitors of alarmins and immuno-
suppressive cytokines. (C) Strategies targeting DCs in vivo include
administration of activation stimuli (Poly I:C, CD40L, Flt3L), in vivo delivery
of tumor antigens, and administration of tumor antigens coupled with
antibody against DC surface receptors.
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DCs for immunotherapeutic use. DC-based immunotherapies
require optimization at several levels: the maturation stimuli used,
the type and form of antigen to be administered, the subset and the
number of DCs to inject, and the frequency, route, and site of the
injection. Studies in humans and mice have emphasized that differ-
ent DC subsets are endowed with specialized functions, and a good
vaccine should utilize these subsets in a coordinated way. Ques-
tions remain as to whether the classical ex vivo-generated moDCs
widely used in immunotherapy are the most effective means of
inducing clinically significant anti-tumor immunity. Some studies
use DCs derived from CD34+ precursors (43) or in vivo-expanded
circulating DCs using Flt3L. Recent findings provide the basis for
a new approach relying on BDCA3+ DCs as anti-tumor vaccines,
as they seem to be a key subset for cross-presentation of cell-
associated antigens (44). Further characterization of these DCs
will enable rational approaches to target them to improve vaccine
efficacy. Looking forward, the main challenge for using BDCA3+
DCs will be to develop an efficient way to generate them in large
numbers. Alternative vaccination strategies such as the delivery
of tumor antigens in vivo to BDCA3+ DC subsets using anti-
bodies specific to cell surface receptors such as CLEC9A has been
proposed. However, more recent findings previously discussed (2,
3) suggest that this approach may not offer an inherent advan-
tage and that the optimal strategy would be to target antigens to
early endosomes. This approach would not only increase cross-
presentation by BDCA3+ DCs but also extend cross-presentation
to more abundant DC subsets therefore maximizing CD8+ T-cell
responses in vivo. It is worth pointing out that Dendreon uses
circulating blood DCs as the adjuvant, not the commonly used
moDCs. A large study directly comparing all DC subsets side by
side for their capacity to induce CTL and TH1 responses after
activation with various stimuli is warranted.
Another critical parameter to induce DC-mediated potent anti-
tumor responses is the choice of DC maturation stimuli. Indeed,
proper DC maturation prior to vaccination is necessary to prevent
induction of tolerance through Tregs. To mature DCs, some clin-
ical trials have used a standardized cocktail of pro-inflammatory
cytokines composed of TNF-α, IL-1β, IL-6, and PGE2 that was
shown to induce up-regulation of MHC molecules, co-stimulatory
molecules as well as CCR7 (45). However, other findings have
suggested that DC matured with this cytokine cocktail were not
optimal as they fail to induce IL-12p70 production and may induce
Treg and TH2 cells (46–48). A novel cytokine cocktail consisting of
TNF-α, IL-1β, Poly I:C, IFN-α, and IFNγ has shown good results
including DC-mediated IL-12 secretion (49, 50). Alternative mat-
uration strategies via direct administration of immune activators
such as TLR agonists, Flt3L, or CD40L has been shown to improve
DC function in vivo (51). Several TLR ligands are currently being
tested in clinical trials including LPS (TLR4),CpG (TLR9),Poly I:C
(TLR3), Imiqiuimod (TLR7), and Resiquimod (TLR7 and TLR8).
Another factor that may explain the limited success of DC-
based vaccines is the less-than optimal migration of DC vaccines
to secondary lymphoid organs. Studies showed that most of the
injected DCs remain at the site of injection, <5% reaching the
draining lymph nodes (52). Administration of DCs via multiple
routes or directly into the lymph nodes may improve DC migration
and clinical responses.
Finally, it’s worth mentioning that most of the clinical trials
treat patients with late stage cancers, whereas the most suitable
stage for cancer vaccine is likely to be early disease when tumor
volume is low.
In vivo delivery of antigens (non-targeted vaccines)
Contrary to previous assumptions, we showed that DC vaccines
have an insignificant role in directly priming CD8+ T cells, but
instead function primarily as vehicles for transferring antigens to
endogenous APCs, which are responsible for the subsequent acti-
vation of T cells (53). This finding highlights the need to develop
strategies directly targeting endogenous DCs. Moreover, in vivo
targeting of DCs represents a more economical option for DC
immunotherapy as it bypasses the expensive and labor-extensive
ex vivo DC generation process described previously.
Tumors express several well-characterized antigens that are rec-
ognized by the immune system. TAA can be antigens derived
from oncogenic viruses (human papilloma virus E6 and E7 pro-
teins), the products of mutations, differentiation antigens (tyrosi-
nase, TRP-1, TRP-2, gp100, Melan A/MART1), overexpressed
variants (Her2/neu), or self-antigens specifically upregulated on
tumors. Strategies that target antigen presentation on both MHC-
I and II molecules are ideal as both CD4+ and CD8+ T cells
are required to launch potent protective anti-tumor immune
response. Immunotherapies using short peptides from tumor
antigens present limitations because they can only be used in
patients with known HLA alleles that present these epitopes in
the absence of natural processing. Alternatively, full-length protein
vaccines often suffer from lack of consistent CD8+ T-cell induc-
tion, likely due to inefficient cross-presentation of the exogenous
antigen by DCs. In contrast, synthetic long peptides are efficiently
presented to both CD4+ and CD8+ T cells by DCs as well as
non-professional APCs (54). The use of bacterial and viral vec-
tors represents another alternative for loading tumor antigens on
DCs. Genes encoding TAAs are inserted into the vector while gene
encoding virulence of replication factors are deleted out. In some
case, the vector may encode for cytokines and co-stimulatory mol-
ecules and therefore induce maturation of DCs, thereby bypassing
the need for a separate maturation stimuli (55). The disadvantage
of the method is that pre-existing immunity against the bacte-
ria or virus vector may reduce their ability to induce immune
responses.
Antigens coupled with DC surface antigens (in vivo targeting of DCs)
Endogenous DCs can be targeted to either deliver tumor-
associated-antigens and/or to provide co-stimulatory signals. Can-
didates for the targeting of DC-specific molecules include Fc
receptors, CD40, and C-type lectin receptors such as DEC-205,
DC-SIGN, CLEC9A, mannose receptor, and Dectin-1. TAAs can be
directly delivered in vivo using chimeric proteins composed of an
antibody that is specific for the DC receptor fused to a selected anti-
gen or to long peptides. Specific targeting of antigens to DCs in vivo
has been shown to elicit potent CD4+ T-cell responses as well
as an enhancement of antibody responses (56–58). CD8+ T-cell
responses are less efficiently induced, unless boosted in a “prime”
fashion such as with pox vectors (59). To avoid the induction
of antigen-specific tolerance, this strategy requires DC activation
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signals. Most of the studies are performed in mice and further
investigations are needed to determine the efficacy in humans and
to identify the best candidate to target.
Optimizing DC vaccines is necessary but to be successful,
immunotherapeutic approaches also need to overcome TME-
induced immune suppression to be able to potentiate the efficacy
of DC vaccines in vivo and translate to overall improved clinical
outcomes.
THERAPIES TARGETING TME
Among the most promising approaches to activating therapeu-
tic anti-tumor immunity is the blockade of immune check-
points. Among checkpoint molecules, CTLA-4 blockade was the
first shown to enhance anti-tumor responses (58). CTLA-4 is
an homolog of CD28 whose binding to its ligands CD80 and
CD86 induces an inhibitory signals to CTLA-4-expressing T cells.
CTLA-4 blockade using neutralizing antibodies (Ipilimumab and
Tremelimumab) targets both effector and regulatory Tregs and has
been shown to enhance immune responses and show promising
clinical responses in melanoma patients (60). Ipilimumab (Yer-
voy) has recently been approved by the FDA for the treatment of
unresectable or metastatic melanoma, based on improved over-
all survival in treated patients (61). Anti-CTLA-4 treatment is
currently being tested for other cancers.
PD-L1, a ligand for the exhaustion marker PD-1, is expressed
by different TME-infiltrating cell types including DCs. Block-
ade of PD-L1 induced durable tumor regression and prolonged
stabilization of disease in patients with advanced cancers, includ-
ing non-small-cell lung cancer, melanoma, and renal-cell can-
cer (62). Moreover, clinical trials using an anti-PD-1 antibody
(nivolumab) reported promising results in patients with advanced
cancer (63). Nivolumab is now in phase III testing. Interestingly,
early results presented at the ASCO 2013 meeting suggested higher
response rates to PD-1 pathway blockade in patients whose tumors
express PD-L1, while combinatorial blockade of CTLA-4 and PD-1
increased anti-tumor immunity when compared to blocking either
single checkpoint alone, although toxicity was higher (Grosso,
abstract #3016; Callahan, abstract #9012).
Similarly to CTLA-4 and PD-1, Tim-3 belongs to the group
of immune checkpoints and is a potential therapeutic target.
Although there is no clinical data yet, Tim-3 has been reported
to be co-expressed with PD-1 on human tumor-specific CD8+ T
cells, and dual blockade of both molecules significantly enhances
the in vitro proliferation and cytokine production of human T cells
(64–66). In vivo studies have shown that Tim-3 blockade alone,
or in combination with PD-1 blockade, is able to control tumor
growth in four different tumor models, including melanoma (66,
67). Moreover, recent findings have shown that tumor-infiltrating
DCs suppress nucleic acid-mediated innate immune responses
through interactions between the receptor TIM-3 and the alarmin
HMGB1 (68) therefore defining a new mechanism whereby the
TME suppresses anti-tumor immunity. We found that NK cells
from melanoma patients were dysfunctional/exhausted and that
Tim-3 blockade was able to reverse this exhausted phenotype and
improve NK cell function. Altogether, those findings suggest that
Tim-3 blockade would improve anti-tumor immunity by not only
targeting T cells, but also DCs and NK cells.
CONCLUSION
Dendritic cells have the potential to initiate specific anti-tumor
immune responses, but several components of TME can modify
their phenotype and function to transform immuno-competent
DCs into immuno-suppressive DCs. The TME not only abrogates
specific T-cell response but also induces DCs to exert immuno-
suppressive and pro-angiogenic functions. Thus, combinatorial
approaches that (1) reprogram the immuno-suppressive TME;
(2) improve DC function; and (3) enhance T-cell immunity,
should provide durable tumor-specific immunity and hold the
most promise for successful immune-base cancer therapies.
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